Log in

PAVM PAVmed Inc. NASDAQ · United States

PAVmed (PAVM) news PAVM offering news

Latest PAVmed news

  1. Company Updates

    PAVmed reports first quarter 2026 results and simpler capital structure

    PAVmed ended the first quarter with $6.5 million in cash, and Lucid Diagnostics' underwritten offering netted about $17 million.

PAVmed annual financials

LineFY2025FY2024
Revenue$3.0 million
Research and development$4.5 million$5.9 million
Net income (loss)$401,000$39.8 million
Cash from operations-$5.2 million-$33.6 million
Cash and equivalents$1.5 million$1.2 million

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $3.8 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about PAVmed

Has PAVmed raised money recently?

Our latest story on this, dated May 15, 2026: "PAVmed reports first quarter 2026 results and simpler capital structure". The story links the filing or release it is based on. Read the story.

What is the ticker symbol of PAVmed?

PAVmed Inc. trades under the ticker PAVM on NASDAQ.

Where is PAVmed listed?

PAVmed Inc. is listed on NASDAQ.

Which country or territory is PAVmed listed under?

Our directory records PAVmed Inc. under United States.

Does aibio.space cover PAVmed?

aibio.space lists PAVmed Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Is PAVmed profitable?

PAVmed Inc. reported net income of $401,000 for the fiscal year ended Dec 31, 2025, and used $5.2 million of cash in operations, per its annual report to the SEC.

How much does PAVmed spend on research and development?

$4.5 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does PAVmed have?

$3.8 million in cash at Jun 30, 2026, per its 10-Q.

What is the latest PAVmed (PAVM) stock news?

Our latest story on PAVmed, dated Aug 14, 2026: "PAVmed reports second quarter 2026 results and Lucid coverage policy". Lucid Diagnostics recognized $1.5 million in EsoGuard revenue in the second quarter, and PAVmed reported cash of $3.8 million at June 30, 2026. Source.

How can I follow PAVmed (PAVM) news?

Press Follow on this page to add PAVmed to your Following list, or subscribe to the aibio.space newsletter. We have published 2 stories naming PAVmed so far, in Company Updates.

Investor discussion: PAVmed

Members talk about PAVmed (PAVM). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at PAVmed, newest first. Each line links the filing it comes from.

  1. Financings

    Reported a financing. SEC Form 8-K (Items 1.01,3.03,9.01). Source

  2. Financings

    Reported a financing. SEC Form 424B5. Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:PAVM on TradingView.

Listing details

PAVmed Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker PAVM, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
PAVmed Inc.
Ticker
PAVM
Listing
NASDAQ
Country or territory
United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.